Showing 1196 results
- Key Release /Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline…
- Media Release /Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent® (siponimod) had a meaningful benefit on cognitive…
- Media Release /Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing…
- Media Release /Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS)[1], a stage of the disease leading to continuous functional decline, which is often undiagnosed or…
- Media Release /Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101…
- Media Release /After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study…
- Media Release /Novartis leads the way at AAN with 52 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple…
- Key Release /En raison du Covid-19 les résultats du S1 sont plus représentatifs de la performance sous-jacente que ceux du T2, croissance de 6% (tcc1, +3% USD) du chiffre d’affaires et de 19% (tcc, +14% USD) du…
- Media Release /Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19…
- Media Release /Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when…
Pagination
- ‹ Previous page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- …
- 120
- › Next page